BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhou C, Kim SW, Reungwetwattana T, Zhou J, Zhang Y, He J, Yang JJ, Cheng Y, Lee SH, Bu L, Xu T, Yang L, Wang C, Liu T, Morcos PN, Lu Y, Zhang L. Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study. Lancet Respir Med 2019;7:437-46. [PMID: 30981696 DOI: 10.1016/S2213-2600(19)30053-0] [Cited by in Crossref: 117] [Cited by in F6Publishing: 125] [Article Influence: 29.3] [Reference Citation Analysis]
Number Citing Articles
1 Pruis MA, Veerman GM, Hassing HC, Lanser DA, Paats MS, van Schaik RH, Mathijssen RH, Manintveld O, Dingemans AC. Cardiac Side Effects of Alectinib in Patients With ALK-Positive Lung Cancer. JACC: CardioOncology 2023. [DOI: 10.1016/j.jaccao.2022.09.006] [Reference Citation Analysis]
2 Cho BC, Kim DW, Batra U, Park K, Kim SW, Yang CT, Voon PJ, Sriuranpong V, Babu KG, Amin K, Wang Y, Sen P, Slimane K, Geater S. Efficacy and Safety of Ceritinib 450 mg/day with Food and 750 mg/day in Fasted State in Treatment-Naïve Patients with ALK+ Non-Small Cell Lung Cancer: Results from the ASCEND-8 Asian Subgroup Analysis. Cancer Res Treat 2023;55:83-93. [PMID: 35344649 DOI: 10.4143/crt.2021.1571] [Reference Citation Analysis]
3 Hendriks L, Kerr K, Menis J, Mok T, Nestle U, Passaro A, Peters S, Planchard D, Smit E, Solomon B, Veronesi G, Reck M. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology 2023. [DOI: 10.1016/j.annonc.2022.12.009] [Reference Citation Analysis]
4 El Sayed R, Tehfe M, Blais N. Successful Treatment with Brigatinib after Alectinib-Induced Hemolytic Anemia in Patients with Metastatic Lung Adenocarcinoma-A Case Series. Curr Oncol 2022;30:518-28. [PMID: 36661690 DOI: 10.3390/curroncol30010041] [Reference Citation Analysis]
5 Yuan D, Zhu F, Zuo R, Wang Y, Huo G, Cui J, Yue P, Chen P. High incidence and reversible bradycardia events following alectinib initiation. Thoracic Cancer 2022. [DOI: 10.1111/1759-7714.14769] [Reference Citation Analysis]
6 Feng W, Bai X. Upregulated HMGB3 resulting in the poor prognosis of lung adenocarcinoma by activating stromal angiogenesis through immune microenvironment.. [DOI: 10.21203/rs.3.rs-2372749/v1] [Reference Citation Analysis]
7 Shen Z, Qiu B, Li L, Yang B, Li G. Targeted therapy of RET fusion-positive non-small cell lung cancer. Front Oncol 2022;12:1033484. [PMID: 36582799 DOI: 10.3389/fonc.2022.1033484] [Reference Citation Analysis]
8 Cicin I, Martin C, Haddad CK, Kim S, Smolin A, Abdillah A, Yang X. ALK TKI therapy in patients with ALK-positive non-small cell lung cancer and brain metastases: A review of the literature and local experiences. Critical Reviews in Oncology/Hematology 2022;180:103847. [DOI: 10.1016/j.critrevonc.2022.103847] [Reference Citation Analysis]
9 Ahn MJ, Kim HR, Yang JCH, Han JY, Li JY, Hochmair MJ, Chang GC, Delmonte A, Lee KH, Campelo RG, Gridelli C, Spira AI, Califano R, Griesinger F, Ghosh S, Felip E, Kim DW, Liu Y, Zhang P, Popat S, Camidge DR. Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK-Inhibitor-Naive ALK+ Non-Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Study. Clin Lung Cancer 2022;23:720-30. [PMID: 36038416 DOI: 10.1016/j.cllc.2022.07.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Zhong WX, Wei XF. Coexistence of anaplastic lymphoma kinase rearrangement in lung adenocarcinoma harbouring epidermal growth factor receptor mutation: A single-center study. World J Clin Cases 2022; 10(33): 12164-12174 [DOI: 10.12998/wjcc.v10.i33.12164] [Reference Citation Analysis]
11 Dziadziuszko R, Peters S, Ruf T, Cardona A, Guerini E, Kurtsikidze N, Smoljanovic V, Planchard D. Clinical experience and management of adverse events in patients with advanced ALK-positive non-small-cell lung cancer receiving alectinib. ESMO Open 2022;7:100612. [PMID: 36375271 DOI: 10.1016/j.esmoop.2022.100612] [Reference Citation Analysis]
12 Tao J, Zheng C, Zhang C, Zhou L, Liu Z, Zhou Y, Huang X, Lin L, Zhai L. First-line treatments for patients with advanced ALK gene rearrangements in NSCLC: a systematic review and network meta-analysis. J Int Med Res 2022;50:030006052211327. [DOI: 10.1177/03000605221132703] [Reference Citation Analysis]
13 Duruisseaux M, Descourt R, Moro-sibilot D. Les patients ALK et ROS1 : quelle séquence ? Revue des Maladies Respiratoires Actualités 2022;14:2S178-2S188. [DOI: 10.1016/s1877-1203(22)00118-5] [Reference Citation Analysis]
14 Cognigni V, Pecci F, Lupi A, Pinterpe G, De Filippis C, Felicetti C, Cantini L, Berardi R. The Landscape of ALK-Rearranged Non-Small Cell Lung Cancer: A Comprehensive Review of Clinicopathologic, Genomic Characteristics, and Therapeutic Perspectives. Cancers 2022;14:4765. [DOI: 10.3390/cancers14194765] [Reference Citation Analysis]
15 Luo X, Zhou Z, Zeng X, Peng L, Liu Q. Cost-effectiveness of ensartinib, crizotinib, ceritinib, alectinib, brigatinib and lorlatinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer in China. Front Public Health 2022;10:985834. [PMID: 36211665 DOI: 10.3389/fpubh.2022.985834] [Reference Citation Analysis]
16 Jiang J, Zhao C, Zhang F, Liu Z, Zhou K, Ren X, Wan Y. ALK inhibitors in ALK-rearranged non-small cell lung cancer with and without brain metastases: systematic review and network meta-analysis. BMJ Open 2022;12:e060782. [PMID: 36123063 DOI: 10.1136/bmjopen-2022-060782] [Reference Citation Analysis]
17 Chen P, Liu Y, Wen Y, Zhou C. Non-small cell lung cancer in China. Cancer Commun (Lond) 2022. [PMID: 36075878 DOI: 10.1002/cac2.12359] [Reference Citation Analysis]
18 Cranmer H, Kearns I, Young M, Humphries MJ, Trueman D. The cost-effectiveness of brigatinib in adult patients with ALK inhibitor–naive ALK-positive non–small cell lung cancer from a US perspective. JMCP 2022;28:970-979. [DOI: 10.18553/jmcp.2022.28.9.970] [Reference Citation Analysis]
19 Wen Y, Jiang T, Wu X, Peng H, Ren S, Zhou C. Front-line treatment for advanced non-small-cell lung cancer and ALK fusion: a network meta-analysis. Ther Adv Med Oncol 2022;14:17588359221116607. [PMID: 36032351 DOI: 10.1177/17588359221116607] [Reference Citation Analysis]
20 Itchins M, Pavlakis N. The quantum leap in therapeutics for advanced ALK+ non-small cell lung cancer and pursuit to cure with precision medicine. Front Oncol 2022;12:959637. [DOI: 10.3389/fonc.2022.959637] [Reference Citation Analysis]
21 Bernabé-Caro R, Garrido P, García-Campelo R, Palmero R, Artal Á, Bayona C, Rodríguez-Abreu D, López-Brea M, Paredes A, Vicente D, Sánchez Torres JM, Majem M, Diz P, Gordo R, Coca M, de Castro J. Alectinib after failure to crizotinib in patients with ALK-positive non-small cell lung cancer: results from the Spanish early access program. Oncotarget 2022;13:812-27. [PMID: 35720977 DOI: 10.18632/oncotarget.28244] [Reference Citation Analysis]
22 Giunta EF, Signori A, West HJ, Metro G, Friedlaender A, Parikh K, Banna GL, Addeo A. Beyond Crizotinib: A Systematic Review and Meta-Analysis of the Next-Generation ALK Inhibitors as First-Line Treatment for ALK-Translocated Lung Cancer. Front Oncol 2022;12:921854. [DOI: 10.3389/fonc.2022.921854] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Reckamp KL, Lin HM, Cranmer H, Wu Y, Zhang P, Walton LJ, Kay S, Cichewicz A, Neupane B, Fahrbach K, Popat S, Camidge DR. Indirect comparisons of brigatinib and alectinib for front-line ALK-positive non-small-cell lung cancer. Future Oncol 2022. [PMID: 35608148 DOI: 10.2217/fon-2022-0194] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Yu Y, Zhu F, Zhang W, Lu S. Comparison of Efficacy and Safety of Brigatinib in First-Line Treatments for Patients with Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Systematic Review and Indirect Treatment Comparison. J Clin Med 2022;11:2963. [PMID: 35683354 DOI: 10.3390/jcm11112963] [Reference Citation Analysis]
25 Kang S, Woo J, Kim S. A Systematic Review of Companion Diagnostic Tests by Immunohistochemistry for the Screening of Alectinib-Treated Patients in ALK-Positive Non-Small Cell Lung Cancer. Diagnostics 2022;12:1297. [DOI: 10.3390/diagnostics12051297] [Reference Citation Analysis]
26 Lin K, Lin J, Huang Z, Fu J, Yi Q, Cai J, Khan M, Yuan Y, Bu J. Impact of Smoking on Response to the First-Line Treatment of Advanced ALK-Positive Non-Small Cell Lung Cancer: A Bayesian Network Meta-Analysis. Front Pharmacol 2022;13:881493. [DOI: 10.3389/fphar.2022.881493] [Reference Citation Analysis]
27 Englmeier F, Bleckmann A, Brückl W, Griesinger F, Fleitz A, Nagels K. Clinical benefit and cost-effectiveness analysis of liquid biopsy application in patients with advanced non-small cell lung cancer (NSCLC): a modelling approach. J Cancer Res Clin Oncol. [DOI: 10.1007/s00432-022-04034-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Tabbò F, De Filippis M, Jacobs F, Novello S. Strengths and pitfalls of brigatinib in non-small cell lung cancer patients' management. Minerva Med 2022;113. [DOI: 10.23736/s0026-4806.21.07693-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Kharagezov DA, Lazutin YN, Mirzoyan EA, Milakin AG, Stateshny ON, Leyman IA, Gappoeva MA, Vitkovskaya VN, Iozefi KD. Modern treatment of ALK-positive non-small cell lung cancer. jour 2022;3:41-51. [DOI: 10.37748/2686-9039-2022-3-2-5] [Reference Citation Analysis]
30 Tao Y, Zhou Y, Tang L, Chen H, Feng Y, Shi Y. Toxicity profile of anaplastic lymphoma kinase tyrosine kinase inhibitors for patients with non-small cell lung cancer: A systematic review and meta-analysis. Invest New Drugs. [DOI: 10.1007/s10637-022-01242-6] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Calabrese F, Pezzuto F, Lunardi F, Fortarezza F, Tzorakoleftheraki S, Resi MV, Tiné M, Pasello G, Hofman P. Morphologic-Molecular Transformation of Oncogene Addicted Non-Small Cell Lung Cancer. IJMS 2022;23:4164. [DOI: 10.3390/ijms23084164] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
32 Liu Y, Chen C, Rong C, He X, Chen L. Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor-Associated Cardiotoxicity: A Recent Five-Year Pharmacovigilance Study. Front Pharmacol 2022;13:858279. [PMID: 35370632 DOI: 10.3389/fphar.2022.858279] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
33 Gao T, Li C, He X, Zhang T. Chemotherapy versus alectinib for the treatment of crizotinib-pretreated ALK-positive patients with non small cell lung cancer: A protocol for systematic review and meta-analysis. Medicine (Baltimore) 2022;101:e29064. [PMID: 35356928 DOI: 10.1097/MD.0000000000029064] [Reference Citation Analysis]
34 Mithoowani H, Febbraro M. Non-Small-Cell Lung Cancer in 2022: A Review for General Practitioners in Oncology. Current Oncology 2022;29:1828-39. [DOI: 10.3390/curroncol29030150] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
35 Tan AC, Tan SH, Zhou S, Peters S, Curigliano G, Tan DS. Efficacy of targeted therapies for oncogene-driven lung cancer in early single-arm versus late phase randomized clinical trials: A comparative analysis. Cancer Treatment Reviews 2022;104:102354. [DOI: 10.1016/j.ctrv.2022.102354] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
36 Tan AC, Tan DSW. Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations. J Clin Oncol 2022;40:611-25. [PMID: 34985916 DOI: 10.1200/JCO.21.01626] [Cited by in Crossref: 29] [Cited by in F6Publishing: 36] [Article Influence: 29.0] [Reference Citation Analysis]
37 Zou Z, Xing P, Hao X, Wang Y, Song X, Shan L, Zhang C, Liu Z, Ma K, Dong G, Li J. Intracranial efficacy of alectinib in ALK-positive NSCLC patients with CNS metastases-a multicenter retrospective study. BMC Med 2022;20:12. [PMID: 35039026 DOI: 10.1186/s12916-021-02207-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
38 Wolf J, Helland Å, Oh IJ, Migliorino MR, Dziadziuszko R, Wrona A, de Castro J, Mazieres J, Griesinger F, Chlistalla M, Cardona A, Ruf T, Trunzer K, Smoljanovic V, Novello S. Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK-positive non-small-cell lung cancer. ESMO Open 2022;7:100333. [PMID: 35042152 DOI: 10.1016/j.esmoop.2021.100333] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
39 Yin Q, Li P, Wang P, Zhang Z, Liu Q, Sun Z, Li W, Ma L, Wang X. Alectinib Together with Intracranial Therapies Improved Survival Outcomes in Untreated ALK-Positive Patients with Non-Small-Cell Lung Cancer and Symptomatic and Synchronic Brain Metastases: A Retrospective Study. Onco Targets Ther 2021;14:5533-42. [PMID: 35002258 DOI: 10.2147/OTT.S345439] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
40 Cameron LB, Hitchen N, Chandran E, Morris T, Manser R, Solomon BJ, Jordan V. Targeted therapy for advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer. Cochrane Database Syst Rev 2022;1:CD013453. [PMID: 34994987 DOI: 10.1002/14651858.CD013453.pub2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
41 Coakley M, Popat S. Molecular Targetable Pathways—ALK. Encyclopedia of Respiratory Medicine 2022. [DOI: 10.1016/b978-0-12-801238-3.11701-5] [Reference Citation Analysis]
42 Taslimi S, Brar K, Ellenbogen Y, Deng J, Hou W, Moraes FY, Glantz M, Zacharia BE, Tan A, Ahluwalia MS, Khasraw M, Zadeh G, Mansouri A. Comparative Efficacy of Systemic Agents for Brain Metastases From Non-Small-Cell Lung Cancer With an EGFR Mutation/ALK Rearrangement: A Systematic Review and Network Meta-Analysis. Front Oncol 2021;11:739765. [PMID: 34950579 DOI: 10.3389/fonc.2021.739765] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
43 Vogelbaum MA, Brown PD, Messersmith H, Brastianos PK, Burri S, Cahill D, Dunn IF, Gaspar LE, Gatson NTN, Gondi V, Jordan JT, Lassman AB, Maues J, Mohile N, Redjal N, Stevens G, Sulman E, van den Bent M, Wallace HJ, Weinberg JS, Zadeh G, Schiff D. Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline. J Clin Oncol 2021;:JCO2102314. [PMID: 34932393 DOI: 10.1200/JCO.21.02314] [Cited by in Crossref: 34] [Cited by in F6Publishing: 48] [Article Influence: 17.0] [Reference Citation Analysis]
44 Ma HC, Liu YH, Ding KL, Liu YF, Zhao WJ, Zhu YJ, Chang XS, Chen YD, Xiao ZZ, Yu YY, Zhou R, Zhang HB. Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with ALK-rearranged: a meta-analysis of clinical trials. BMC Cancer 2021;21:1278. [PMID: 34836510 DOI: 10.1186/s12885-021-08977-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
45 Peng L, Lu D, Xia Y, Hong S, Selvaggi G, Stebbing J, Sun Y, Liang F. Efficacy and Safety of First-Line Treatment Strategies for Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Bayesian Network Meta-Analysis. Front Oncol 2021;11:754768. [PMID: 34820326 DOI: 10.3389/fonc.2021.754768] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
46 Fjaellegaard K, Koefod Petersen J, Andersen G, Biagini M, Bhatnagar R, Laursen CB, Clementsen PF, Bodtger U. The prevalence of tumour markers in malignant pleural effusions associated with primary pulmonary adenocarcinoma: a retrospective study. Eur Clin Respir J 2021;8:1984375. [PMID: 34745460 DOI: 10.1080/20018525.2021.1984375] [Reference Citation Analysis]
47 Wang Y, Jiang F, Xia R, Li M, Yao C, Li Y, Li H, Zhao Q, Shi M, Yu Y, Shao YW, Zhou G, Xia H, Miao L, Cai H. Unique Genomic Alterations of Cerebrospinal Fluid Cell-Free DNA Are Critical for Targeted Therapy of Non-Small Cell Lung Cancer With Leptomeningeal Metastasis. Front Oncol 2021;11:701171. [PMID: 34671549 DOI: 10.3389/fonc.2021.701171] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
48 Zhao B, Han Y, Wang Y, Wang Y, Wang Y, Xing H, Dai C, Wang Y, Wang H, Ma W. A Bayesian network meta-analysis regarding the comparative efficacy of therapeutics for ALK-positive, brain metastatic non-small cell lung cancer. Pharmacol Res 2021;174:105931. [PMID: 34626769 DOI: 10.1016/j.phrs.2021.105931] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
49 Li W, Lyu Y, Wang S, Zhou X, Ma J, Xu C, Fang L, Ying J; Experts from the Molecular Pathology Collaboration Group of Tumor Pathology Committee of Chinese Anti-Cancer Association. Trends in Molecular Testing of Lung Cancer in Mainland People's Republic of China Over the Decade 2010 to 2019. JTO Clin Res Rep 2021;2:100163. [PMID: 34590013 DOI: 10.1016/j.jtocrr.2021.100163] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
50 Tan DSW, Geater S, Yu CJ, Tsai CM, Hsia TC, Chen J, Lin MC, Lu Y, Sriuranpong V, Yang CT, Sen P, Branle F, Shi M, Wu YL. Ceritinib Efficacy and Safety in Treatment-Naive Asian Patients With Advanced ALK-Rearranged NSCLC: An ASCEND-4 Subgroup Analysis. JTO Clin Res Rep 2021;2:100131. [PMID: 34589995 DOI: 10.1016/j.jtocrr.2020.100131] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
51 Gibson AJW, Box A, Dean ML, Elegbede AA, Hao D, Sangha R, Bebb DG. Retrospective Real-World Outcomes for Patients With ALK-Rearranged Lung Cancer Receiving ALK Receptor Tyrosine Kinase Inhibitors. JTO Clin Res Rep 2021;2:100157. [PMID: 34590010 DOI: 10.1016/j.jtocrr.2021.100157] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
52 Wu KL, Chen HL, Tsai YM, Lee TH, Chang HM, Tsai YC, Chuang CH, Chang YC, Tu YK, Yang CJ, Hung JY, Chong IW. First-Line Anaplastic Lymphoma Kinase (ALK) Inhibitors for ALK-Positive Lung Cancer in Asian Populations: Systematic Review and Network Meta-Analysis. J Clin Med 2021;10:4376. [PMID: 34640394 DOI: 10.3390/jcm10194376] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
53 Zeng H, Li Y, Wang Y, Huang M, Zhang Y, Tian P, Li W. Case Report: Identification of Two Rare Fusions, PDK1-ALK and STRN-ALK, That Coexist in a Lung Adenocarcinoma Patient and the Response to Alectinib. Front Oncol 2021;11:722843. [PMID: 34485156 DOI: 10.3389/fonc.2021.722843] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
54 Baldacci S, Mascaux C, Cortot A. Oncogenèse pulmonaire : mécanismes généraux et addictions oncogéniques. Revue des Maladies Respiratoires Actualités 2021;13:2S12-2S20. [DOI: 10.1016/s1877-1203(21)00091-4] [Reference Citation Analysis]
55 Bououden W, Benguerba Y, Darwish AS, Attoui A, Lemaoui T, Balsamo M, Erto A, Alnashef IM. Surface adsorption of Crizotinib on carbon and boron nitride nanotubes as Anti-Cancer drug Carriers: COSMO-RS and DFT molecular insights. Journal of Molecular Liquids 2021;338:116666. [DOI: 10.1016/j.molliq.2021.116666] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 7.5] [Reference Citation Analysis]
56 Tanaka I, Furukawa T, Morise M. The current issues and future perspective of artificial intelligence for developing new treatment strategy in non-small cell lung cancer: harmonization of molecular cancer biology and artificial intelligence. Cancer Cell Int 2021;21:454. [PMID: 34446006 DOI: 10.1186/s12935-021-02165-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
57 Adashek JJ, Subbiah IM. Caring for the caregiver: a systematic review characterising the experience of caregivers of older adults with advanced cancers. ESMO Open 2020;5:e000862. [PMID: 32963088 DOI: 10.1136/esmoopen-2020-000862] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 9.5] [Reference Citation Analysis]
58 Ando K, Manabe R, Kishino Y, Kusumoto S, Yamaoka T, Tanaka A, Ohmori T, Sagara H. Comparative Efficacy and Safety of Lorlatinib and Alectinib for ALK-Rearrangement Positive Advanced Non-Small Cell Lung Cancer in Asian and Non-Asian Patients: A Systematic Review and Network Meta-Analysis. Cancers (Basel) 2021;13:3704. [PMID: 34359604 DOI: 10.3390/cancers13153704] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
59 Tang H, Jin L, Zhang Z, Jiang Z, Malik Z. Comparison of Clinical Efficacy of Alectinib Versus Crizotinib in ALK-Positive Non-Small Cell Lung Cancer: A Meta-Analysis. Front Oncol 2021;11:646526. [PMID: 34150615 DOI: 10.3389/fonc.2021.646526] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
60 Pan Y, Xiao W, Ye F, Wang H, Shen Y, Yu X, Han X, Chu Q, Zhou C, Zhang Z, Ren S. Outcomes of switching from crizotinib to alectinib in patients with advanced non-small cell lung cancer with anaplastic lymphoma kinase fusion. Ann Transl Med 2021;9:1014. [PMID: 34277814 DOI: 10.21037/atm-21-2769] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
61 Sun K, Nie L, Nong L, Cheng Y. Primary resistance to alectinib in a patient with STRN-ALK-positive non-small cell lung cancer: A case report. Thorac Cancer 2021;12:1927-30. [PMID: 33960639 DOI: 10.1111/1759-7714.13983] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
62 Hu J, Chen Y, Zhu X, Ma Q, Zhang J, Jiang G, Zhang P. Surgical choice of non-small cell lung cancer with unexpected pleural dissemination intraoperatively. BMC Cancer 2021;21:445. [PMID: 33888088 DOI: 10.1186/s12885-021-08180-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
63 Chuang CH, Chen HL, Chang HM, Tsai YC, Wu KL, Chen IH, Chen KC, Lee JY, Chang YC, Chen CL, Tu YK, Hung JY, Yang CJ, Chong IW. Systematic Review and Network Meta-Analysis of Anaplastic Lymphoma Kinase (ALK) Inhibitors for Treatment-Naïve ALK-Positive Lung Cancer. Cancers (Basel) 2021;13:1966. [PMID: 33921762 DOI: 10.3390/cancers13081966] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]
64 König D, Savic Prince S, Rothschild SI. Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations. Cancers (Basel) 2021;13:804. [PMID: 33671873 DOI: 10.3390/cancers13040804] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 18.0] [Reference Citation Analysis]
65 Casado D, Bellido L, del Barco E, Cigarral B, Escalera E, Claros J, Barrios B, Figuero L, Olivares A, López A, Terán E, Cruz J. Biomarcadores moleculares y celulares. Implicaciones en la terapia dirigida. Medicine - Programa de Formación Médica Continuada Acreditado 2021;13:1418-1423. [DOI: 10.1016/j.med.2021.02.008] [Reference Citation Analysis]
66 Xia B, Nagasaka M, Zhu VW, Ou SI, Soo RA. How to select the best upfront therapy for metastatic disease? Focus on ALK-rearranged non-small cell lung cancer (NSCLC). Transl Lung Cancer Res 2020;9:2521-34. [PMID: 33489815 DOI: 10.21037/tlcr-20-331] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
67 Collazo-lorduy A, Jiménez B, Castro-henriques M, Remon J. ALK rearranged lung cancer: TKI treatment and outcome. Therapeutic Strategies to Overcome ALK Resistance in Cancer 2021. [DOI: 10.1016/b978-0-12-821774-0.00013-9] [Reference Citation Analysis]
68 Gristina V, La Mantia M, Iacono F, Galvano A, Russo A, Bazan V. The Emerging Therapeutic Landscape of ALK Inhibitors in Non-Small Cell Lung Cancer. Pharmaceuticals (Basel) 2020;13:E474. [PMID: 33352844 DOI: 10.3390/ph13120474] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 10.7] [Reference Citation Analysis]
69 Kang J, Zhang XC, Chen HJ, Zhong WZ, Xu Y, Su J, Zhou Q, Tu HY, Wang Z, Xu CR, Yang XN, Chen ZH, Wu X, Zhang X, Shao Y, Wu YL, Yang JJ. Complex ALK Fusions Are Associated With Better Prognosis in Advanced Non-Small Cell Lung Cancer. Front Oncol 2020;10:596937. [PMID: 33363027 DOI: 10.3389/fonc.2020.596937] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
70 Kauffmann-Guerrero D, Kahnert K, Huber RM. Treatment Sequencing for Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer. Drugs 2021;81:87-100. [PMID: 33226527 DOI: 10.1007/s40265-020-01445-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
71 Ding S, Wang R, Peng S, Luo X, Zhong L, Yang H, Ma Y, Chen S, Wang W. Targeted therapies for RET-fusion cancer: Dilemmas and breakthrough. Biomed Pharmacother 2020;132:110901. [PMID: 33125973 DOI: 10.1016/j.biopha.2020.110901] [Reference Citation Analysis]
72 Duruisseaux M, Descourt R, Moro-sibilot D. Les patients ALK et ROS1 : quelle séquence ? Revue des Maladies Respiratoires Actualités 2020;12:2S212-2S222. [DOI: 10.1016/s1877-1203(20)30101-4] [Reference Citation Analysis]
73 Qiao M, Zhao C, Liu Q, Wang Y, Shi J, Ng TL, Zhou F, Li X, Jiang T, Yang S, Gao G, Xiong A, Li J, Li W, Wu F, Chen X, Su C, Ren S, Zhou C, Zhang J. Impact of ALK variants on brain metastasis and treatment response in advanced NSCLC patients with oncogenic ALK fusion. Transl Lung Cancer Res 2020;9:1452-63. [PMID: 32953517 DOI: 10.21037/tlcr-19-346] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
74 Ferrara MG, Di Noia V, D'Argento E, Vita E, Damiano P, Cannella A, Ribelli M, Pilotto S, Milella M, Tortora G, Bria E. Oncogene-Addicted Non-Small-Cell Lung Cancer: Treatment Opportunities and Future Perspectives. Cancers (Basel) 2020;12:E1196. [PMID: 32397295 DOI: 10.3390/cancers12051196] [Cited by in Crossref: 35] [Cited by in F6Publishing: 40] [Article Influence: 11.7] [Reference Citation Analysis]
75 Cheng B, Xiong S, Li C, Liang H, Zhao Y, Li J, Shi J, Ou L, Chen Z, Liang P, Liang W, He J. An annual review of the remarkable advances in lung cancer clinical research in 2019. J Thorac Dis 2020;12:1056-69. [PMID: 32274174 DOI: 10.21037/jtd.2020.03.11] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
76 Elliott J, Bai Z, Hsieh SC, Kelly SE, Chen L, Skidmore B, Yousef S, Zheng C, Stewart DJ, Wells GA. ALK inhibitors for non-small cell lung cancer: A systematic review and network meta-analysis. PLoS One 2020;15:e0229179. [PMID: 32074131 DOI: 10.1371/journal.pone.0229179] [Cited by in Crossref: 32] [Cited by in F6Publishing: 36] [Article Influence: 10.7] [Reference Citation Analysis]
77 Gadgeel S, Shaw AT, Barlesi F, Crino L, Yang JC, Dingemans AM, Kim DW, de Marinis F, Schulz M, Liu S, Gupta R, Smoljanovic V, Ou SI. Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 Studies. Lung Cancer (Auckl) 2019;10:125-30. [PMID: 32009824 DOI: 10.2147/LCTT.S209231] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
78 Iwama E, Goto Y, Murakami H, Tsumura S, Sakashita H, Mori Y, Nakagaki N, Fujita Y, Seike M, Bessho A, Ono M, Nishitsuji M, Akamatsu H, Morinaga R, Akagi T, Shimose T, Tokunaga S, Yamamoto N, Nakanishi Y, Sugio K, Okamoto I. Survival Analysis for Patients with ALK Rearrangement-Positive Non-Small Cell Lung Cancer and a Poor Performance Status Treated with Alectinib: Updated Results of Lung Oncology Group in Kyushu 1401. Oncologist 2020;25:306-e618. [PMID: 32297438 DOI: 10.1634/theoncologist.2019-0728] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
79 Lin JJ, Schoenfeld AJ, Zhu VW, Yeap BY, Chin E, Rooney M, Plodkowski AJ, Digumarthy SR, Dagogo-Jack I, Gainor JF, Ou SI, Riely GJ, Shaw AT. Efficacy of Platinum/Pemetrexed Combination Chemotherapy in ALK-Positive NSCLC Refractory to Second-Generation ALK Inhibitors. J Thorac Oncol. 2020;15:258-265. [PMID: 31669591 DOI: 10.1016/j.jtho.2019.10.014] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 8.5] [Reference Citation Analysis]
80 Liu M, Zhang L, Huang Q, Li N, Zheng B, Cai H. Cost-Effectiveness Analysis Of Ceritinib And Alectinib Versus Crizotinib In The Treatment Of Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer. Cancer Manag Res 2019;11:9195-202. [PMID: 31749634 DOI: 10.2147/CMAR.S223441] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
81 Leipert J, Hammerschmidt S, Geßner C. Medikamentöse Therapie des metastasierten nicht-kleinzelligen Lungenkarzinoms. Pneumologe 2019;16:397-409. [DOI: 10.1007/s10405-019-00284-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
82 Liu C, Yu H, Long Q, Chen H, Li Y, Zhao W, Zhao K, Zhu Z, Sun S, Fan M, Chang J, Wang J. Real World Experience of Crizotinib in 104 Patients With ALK Rearrangement Non-small-cell Lung Cancer in a Single Chinese Cancer Center. Front Oncol 2019;9:1116. [PMID: 31696059 DOI: 10.3389/fonc.2019.01116] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
83 Duruisseaux M, Descourt R, Moro-sibilot D. Les patients ALK et ROS1: quelle séquence ? Revue des Maladies Respiratoires Actualités 2019;11:380-391. [DOI: 10.1016/s1877-1203(19)30107-7] [Reference Citation Analysis]
84 Friedlaender A, Banna G, Patel S, Addeo A. Diagnosis and Treatment of ALK Aberrations in Metastatic NSCLC. Curr Treat Options Oncol. 2019;20:79. [PMID: 31482479 DOI: 10.1007/s11864-019-0675-9] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
85 Yu H, Sun S, Hu X, Xia J, Wang J, Chen H. Chinese perspectives on clinical efficacy and safety of alectinib in patients with ALK-positive advanced non-small cell lung cancer. Onco Targets Ther 2019;12:6481-95. [PMID: 31616158 DOI: 10.2147/OTT.S185115] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]